Breakpoints19 Helmi 2021

#34 – The New Scoop on Poop: Updates in the Management of C. difficile infections

Dr. Kevin Garey (@GareyKgarey), Dr. Kelly Reveles (@KellyReveles), Dr. Mandelin Cooper, and host Dr. Rachel Britt (@RachelBPharmD) discuss proposed updates of the IDSA-SHEA C. difficile guidelines, including: fidaxomicin over oral vancomycin as first-line therapy, the roles and logistical hurdles of fecal microbiota transplant, bezlotoxumab, and the pros and cons of prophylaxis.

Timestamps

1:16 - Panel introductions 3:19 - Fidaxomicin vs PO vancomycin for first occurrence 7:21 - Fidaxomicin cost effectiveness 11:26 - Factors to consider for health systems when considering switch to fidaxomicin 14:23 - Fidaxomicin vs PO vancomycin for recurrences 17:52 - Role of pulsed and tapered PO vancomycin 19:57 - Role of fecal microbiota transplant (FMT) 22:24 - Challenges of FMT and where pharmacy fits in 27:27 - Bezlotoxumab 31:54 - Feasibility issues with bezlotoxumab and strategies to address them 35:25 - CDI prophylaxis 40:28 - Stewardship's role in reducing C. difficile infections

References

Fidaxomicin Cost-effectiveness

Reveles KR, et al. Pharmacotherapy. 2017;37(12):1489-97.
Watt M, et al. Infection. 2016;44(5):599-606.
Cornely OA, et al. J Antimicrob Chemother. 2018;73(9):2529-39.
Rubio-Terres C, et al. Eur J Clin Microbiol Infect Dis. 2019;38(6):1105-11.

Bezlotoxumab

Wilcox MH, et al. N Engl J Med. 2017;376:305-17.
Oksi J, et al. Eur J Clin Microbiol Infect Dis. 2019;38(10):1947-52.
Hengel RL, et al. Open Forum Infect Dis. 2020;7(4):ofaa097.

Bezlotoxumab Cost-effectiveness

Salavert M, et al. Adv Ther. 2018;35(11):1920-34.
Prabhu VS, et al. Clin Infect Dis. 2018;66(3):355-62.

Primary prophylaxis

Pereiras MA, et al. Biol Blood Marrow Transplant. 2017; 23:S395.
Ganetsky A, et al. Clin Infect Dis. 2019;68(12):2003-2009.
Mullane KM, et al. Clin Infect Dis. 2019; 68(2):196–203.

Secondary prophylaxis

Carignan A, et al. Am J Gastroenterol. 2016;111:1834-1840.
Van Hise NW, et al. Clin Infect Dis. 2016;63:651-653.
Splinter et al. Ann Pharmacother. 2018;52:113-119.
Knight EM, et al. J Pharm Pract. 2019;:897190019825994.
Morrisette T, et al. Biol Blood Marrow Transplant. 2019;25(10):2091-2097.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(134)

#6 – Tazobactam and Tulips: Hot Topics from ECCMID 2019

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) review expanded MERINO trial data including mortality by pathogen MIC, PK-PD principles, BLING III, beta-lactam therapeutic drug monitori...

10 Heinä 201930min

#5 – Nerding Out at ECCMID 2019

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) share their secret passions and nerdiest moments from ECCMID 2019, including multi-omics data for Pseudomonas aeruginosa, the effects of ...

10 Heinä 201929min

#4 – How ECCMID 2019 went viral

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) review results of ASPECT-NP (Ceftolozane-tazobactam versus meropenem in patients with ventilated nosocomial pneumonia), CAMERA-2 (Combina...

10 Heinä 201931min

#3 – Lessons Learned From the Front Line

In the final part of our three part series on penicillin allergies host Jason Pogue (@jpogue1) and our expert panelists Julie Ann Justo (@julie_justo), Bruce Jones (@Bruce_M_Jones), and Mary Staicu (@...

26 Kesä 201927min

#2 – Implementing Penicillin Skin Testing

In episode 2 host Jason Pogue (@jpogue1) and panelists Julie Ann Justo (@julie_justo), Bruce Jones (@Bruce_M_Jones), and Mary Staicu (@marylynnstaicu) discuss strategies for allergy reconciliation and...

26 Kesä 201923min

#1 – Mythbusting

In this episode host Jason Pogue (@jpogue1) discusses common misconceptions surrounding penicillin allergies, provides evidence to dispute these misgivings, and describes some of the consequences that...

26 Kesä 201920min